Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Bellway cites lower mortgage rates, improved confidence as H1 profits grow

(Sharecast News) - Housebuilder Bellway hailed a "strong" first half on Tuesday as it posted a 12% increase in underlying pre-tax profit, citing lower mortgage interest rates and improved consumer confidence. In the six months to the end of January 2025, underlying pre-tax profit rose to £150.2m from £134.2m in the same period a year earlier. Revenue was up 12.3% to £1.4bn and housing completions increased 11.9% to 4,577.

The average selling price was £310,581, up from £309,278 a year earlier and the private reservation rate per outlet per week picked up 18.6% to 0.51.

Bellway said trading was ahead of the comparative period, "driven by lower mortgage interest rates and an improvement in consumer confidence".

The housebuilder said that while it did not experience a typical seasonal step-up in reservations in autumn, trading was stable and followed by a notable increase in January 2025.

"Customer demand was further supported by good availability of mortgage finance, although affordability remains relatively constrained for those customers requiring higher loan-to-value mortgages," it said.

Chief executive Jason Honeyman said: "Bellway has delivered a strong first half performance with good growth in volume output and profits. Underlying demand for our homes is healthy and we have been encouraged by the improvement in customer enquiries and reservations since the start of the new calendar year."

He said the company was on track to deliver volume output of at least 8,500 homes in the full year, versus 7,654 at the end of July 2024, and that it currently expects to build the order book through the second half to support further growth in 2026.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.